Healthcare ❯ Pharmaceuticals ❯ Weight Loss Drugs

GLP-1 Drugs

Mounjaro Eli Lilly Novo Nordisk Semaglutide Cigna Tirzepatide Mounjaro and Zepbound Ozempic Wegovy and Ozempic Eli Lilly and Novo Nordisk Eli Lilly and Company Market Competition Misuse Concerns Market Growth Employer Coverage

Eli Lilly Trades at a High Multiple as GLP‑1 Catalysts Loom

Near‑term regulatory decisions and launch results will determine whether investors’ big growth bet on the company is justified.

Generics and Pills Expand Access to GLP‑1s, but Uptake and Coverage Remain Uneven

GSK Gains After Cramer Endorsement as Company Pushes Into Weight-Loss Drugs

Eli Lilly Jumps on GLP‑1 Momentum as 2026 Outlook Beats and Targets Rise

Eli Lilly’s GLP-1 Lead Faces New Pressure From Novo’s Weight-Loss Pill

Eli Lilly Shifts to Access-First Strategy on GLP-1 Strength